Cisplatin/gemcitabine association has been a standard of care for first‐line regimen in
advanced biliary tract cancer nevertheless oxaliplatin/gemcitabine regimen is frequently …

Background Gemcitabine and cisplatin has limited benefit as treatment for advanced biliary
tract cancer (BTC). The addition of an anti‐programmed death receptor (PD‐1)/PD‐ligand …

Biliary tract cancers (BTC) are a relatively rare heterogeneous group of four to five
anatomically distinct cancers whose prognosis is poor, even in the setting of attempted …

Background Current data suggest that chemotherapy combinations may be superior to
single agents in biliary tract cancer. The epidermal growth factor receptor (EGFR) pathway …

Background: Current data suggest that platinum-based combination therapy is the standard
first-line treatment for biliary tract cancer. EGFR inhibition has proven beneficial across a …

Background Cholangiocarcinomas are uncommon tumours with a poor prognosis, that
frequently present epidermal growth factor receptor overexpression. Methods In a multi …

Background: In biliary tract cancer, gemcitabine platinum (GP) doublet palliative
chemotherapy is the current standard treatment. The aim of this study was to analyze recent …

Chemotherapy is indispensable for the treatment of advanced biliary tract cancer. Recently,
reports regarding first-line chemotherapy have increased, and first-line chemotherapy …

Biliary tract cancers (BTC), though uncommon, are highly fatal malignancies, and current
treatments fail to cure or control the majority of tumors. Given the complexity of the anatomy …

State-of-the-art in the management of locally advanced and m... : Current Opinion in Oncology
State-of-the-art in the management of locally advanced and metastatic gallbladder cancer …